Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ReFacto vs Advate in Hemophilia A
NCT00168051Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2005
- Primary completion
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of moroctocog alfa in hemophilia A (2 arms), sponsored by Pfizer. Primary endpoint: Area under the plasma Factor VIII activity versus time curve at 48 hours. Planned start Apr 2005; status: withdrawn.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00168051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168051.